TY - JOUR
T1 - Bronchodilator reversibility testing in morbidly obese non-smokers
T2 - a comparative study– few concerns
AU - Balan, Divya
AU - Shetty, Manish R.
AU - Mohan, Manu K.
N1 - Publisher Copyright:
© The Author(s) 2024.
PY - 2024/12
Y1 - 2024/12
N2 - This is a letter in response to an article by Ahmed et al., which concluded that in comparison to salbutamol, Fluticasone/salmeterol combination increases FEV1, FEV1% of predicted, and FEV1/FVC ratio, however it did not offer novel insights, as both agents met the 12%- and 200-mL reversibility benchmarks and Concerns about incorporating a combination medication that includes an inhaled corticosteroid, inhaled corticosteroids are not typically associated with bronchodilation.
AB - This is a letter in response to an article by Ahmed et al., which concluded that in comparison to salbutamol, Fluticasone/salmeterol combination increases FEV1, FEV1% of predicted, and FEV1/FVC ratio, however it did not offer novel insights, as both agents met the 12%- and 200-mL reversibility benchmarks and Concerns about incorporating a combination medication that includes an inhaled corticosteroid, inhaled corticosteroids are not typically associated with bronchodilation.
UR - http://www.scopus.com/inward/record.url?scp=85187969117&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85187969117&partnerID=8YFLogxK
U2 - 10.1186/s12890-024-02951-9
DO - 10.1186/s12890-024-02951-9
M3 - Article
C2 - 38491503
AN - SCOPUS:85187969117
SN - 1471-2466
VL - 24
JO - BMC Pulmonary Medicine
JF - BMC Pulmonary Medicine
IS - 1
M1 - 132
ER -